NYVAC vaccine

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2017
024620002017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
We compared the HIV-1-specific immune responses generated by targeting HIV-1 envelope protein (Env gp140) to either CD40 or LOX-1… (More)
  • table 3
  • table 4
  • table 5
  • figure 2
  • figure 4
Is this relevant?
2016
2016
UNLABELLED In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine field seek to… (More)
Is this relevant?
Review
2015
Review
2015
UNLABELLED We compared the HIV-1-specific cellular and humoral immune responses elicited in rhesus macaques immunized with two… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Viruses have developed strategies to counteract signalling through Toll-like receptors (TLRs) that are involved in the detection… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regimen using a canarypox vector… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 5
  • figure 6
Is this relevant?
2012
2012
Methods The rAd5 vaccine expressed clade B Gag-Pol and the gp140 of HIV-1 92RW020 (clade A), HxB2/Bal-V3/ ΔV1V2 (clade B) and… (More)
Is this relevant?
2012
2012
Background HVTN 078 is a phase 1b clinical trial of heterologous vector prime/boost vaccine regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC… (More)
Is this relevant?
2009
2009
As part of a European initiative (EuroVacc), we report the design, construction, and immunogenicity of two HIV-1 vaccine… (More)
Is this relevant?
2007
2007
In this investigation we have generated and defined the immunogenicity of two novel HIV/AIDS vaccine candidates based on the… (More)
Is this relevant?
2000
2000
OBJECTIVES Immunization with attenuated poxvirus-HIV-1 recombinants followed by protein boosting had protected four of eight… (More)
Is this relevant?